Hahm K B, Park I S, Kim Y S, Kim J H, Cho S W, Lee S I, Youn J K
Department of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.
Free Radic Biol Med. 1997;22(4):711-6. doi: 10.1016/s0891-5849(96)00406-6.
Reactive oxygen metabolites (ROM) have been reported to be important in the pathogenesis of ischemia/ reperfusion-, ethanol-, nonsteroidal antiinflammatory drug-, or Helicobacter pylori-induced gastric mucosal injury. Rebamipide, a novel antiulcer agent, has been reported either to prevent various acute experimental gastric mucosal lesions or to accelerate the healing of chronic gastric ulcers. The underlying mechanism by which rebamipide exerts its cytoprotective effect in the damaged stomach is not fully determined. We investigated the role of rebamipide in protecting against ROM-mediated cell damage in gastric mucosal cells and in inducing cytoprotective proteins. Cells were exposed to ROM enzymatically generated by hypoxanthine-xanthine oxidase. Cytotoxicity was quantified by measuring specific 51Cr release from prelabeled cells. ROM caused dose-dependent increase in cytotoxicity and amount of thiobarbituric acid-reactive substances (TBA-RS). ROM-induced cytotoxicity and TBA-RS were dose-dependently decreased by the addition of rebamipide and/or catalase, but not by superoxide dismutase alone. The effects of rebamipide on electric spin resonance signal were investigated. We found that the DMPO spin adduct ESR signal of hydroxyl radicals (DMPO-OH) was significantly attenuated by rebamipide. Western blot analysis showed that induction of heat-shock protein (HSP70) was significantly increased following rebamipide administration in a dose-dependent manner. Based on these results, it is concluded that rebamipide exerted a protective effect on HX-XO-induced gastric mucosal cell cytotoxicity through one or more of the following mechanism(s): (1) inhibition of lipid peroxidation of the cell membrane; (2) hydroxyl radical scavenging activity; and (3) induction of cellular cytoprotective protein such as HSP70.
据报道,活性氧代谢产物(ROM)在缺血/再灌注、乙醇、非甾体抗炎药或幽门螺杆菌诱导的胃黏膜损伤发病机制中起重要作用。瑞巴派特是一种新型抗溃疡药物,据报道它既能预防各种急性实验性胃黏膜损伤,又能加速慢性胃溃疡的愈合。瑞巴派特在受损胃中发挥细胞保护作用的潜在机制尚未完全明确。我们研究了瑞巴派特在保护胃黏膜细胞免受ROM介导的细胞损伤以及诱导细胞保护蛋白方面的作用。将细胞暴露于次黄嘌呤-黄嘌呤氧化酶酶促产生的ROM中。通过测量预先标记细胞中特定的51Cr释放量来定量细胞毒性。ROM导致细胞毒性和硫代巴比妥酸反应性物质(TBA-RS)量呈剂量依赖性增加。添加瑞巴派特和/或过氧化氢酶可使ROM诱导的细胞毒性和TBA-RS呈剂量依赖性降低,但单独使用超氧化物歧化酶则无此作用。研究了瑞巴派特对电子自旋共振信号的影响。我们发现瑞巴派特可显著减弱羟基自由基的DMPO自旋加合物ESR信号(DMPO-OH)。蛋白质印迹分析表明,给予瑞巴派特后热休克蛋白(HSP70)的诱导呈剂量依赖性显著增加。基于这些结果,得出结论:瑞巴派特通过以下一种或多种机制对HX-XO诱导的胃黏膜细胞毒性发挥保护作用:(1)抑制细胞膜脂质过氧化;(2)羟基自由基清除活性;(3)诱导细胞保护蛋白如HSP70。